Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Capsules
Patent
1989-12-11
1991-08-13
Page, Thurman K.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Capsules
424422, 424 10, 514872, 514922, A61K 948, A61K 4900, A61F 1300
Patent
active
050395289
ABSTRACT:
This invention relates to a method and a class of pharmaceutical agents for suppressing vomiting, nausea, and other emetic symptoms. The method involves administering to a susceptible mammal a glutamate (EAA) receptor antagonist at an anti-emetically effective dose which does not cause undesirable side effects. Preferred EAA antagonists include those that do not readily cross blood-brain barriers (BBB). One suitable formulation comprises a broad-spectrum antagonist such as kynurenic acid or 7-chlorokynurenate. Other formulations include EAA antagonists that preferentially block NMDA receptors (such as D-AP5) or non-NMDA receptors (such as CNQX), or mixtures thereof that can block both classes of EAA receptors. In lab tests, the agents of this invention were shown to reduce or entirely block the effects of several emetic agents, including cisplatin. Treated animals did not vomit or exhibit lethargy or malaise and did not display any adverse side effects, while control animals consistently displayed lethargy, malaise, and vomiting.
REFERENCES:
patent: 3976774 (1976-08-01), Conway
patent: 4126687 (1978-11-01), Vandenberk et al.
patent: 4213983 (1980-07-01), Hadley et al.
patent: 4302452 (1981-11-01), Pittman
patent: 4351833 (1982-09-01), Johnson
patent: 4466968 (1984-08-01), Bernstein
patent: 4717563 (1988-01-01), Alphin et al.
patent: 4753789 (1988-06-01), Tyers et al.
patent: 4861781 (1989-08-01), Goldberg
Florczyck, A. P., et al, "Cisplatin induced emesis in the ferret: a new animal model," Cancer Treatment Reports 66: 187-190 (1982).
Davies, J., et al, "Recent Advances in the Pharmacology of Excitatory Amino Acids in the Mammalian Central Nervous System," in Excitotoxins, edited by K. Fuxe et al (Macmillan Press, London, 1983).
Boast, C. A., "Neuroprotection after brain ischemia: role of competitive NMDA antagonists," Neurology and Neurobiology 46: 691-698 (1988).
Herrling, P. L., et al., "NMDA antagonistic properties of the enantiomers of CPP and CPP-ene," Soc. Neurosci. Abstr. 15: 327 (1989).
Honore, T., et al, "Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists," Science 241: 701-703 (1988).
Drejer, J. and Honore, T., "New quinoxalinediones show potent antagonism of quisqualate responses in cultured mouse cortical neurons," Neurosci. Letters 87: 104-108 (1988).
Honore, T., et al, "Quisqualate receptor specific quinoxalinedione (FG 9202, NBQX) blocks kainate induced responses," J. Neurochem. 52: Suppl., S42-A (1989).
Sheardown, M. J., et al, "NBQX, a specific non-NMDA receptor antagonist, shows neuroprotective effects against cerebral ischemia," abstract published in Proceedings of the First International Conference on Therapy with Amino Acids and Analogs, Vienna, Aug. 7-12, 1989.
Kishore G.
Page Thurman K.
LandOfFree
EAA antagonists as anti-emetic drugs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with EAA antagonists as anti-emetic drugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and EAA antagonists as anti-emetic drugs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1526473